Hussain Sabiha M, Marcus Richard J, Ko Tina Y, Nashar Khaled, Thai Ngoc L, Sureshkumar Kalathil K
From the Divisions of Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
Exp Clin Transplant. 2016 Jun;14(3):287-93.
This study explored the safety of early steroid withdrawal in recipients of expanded criteria deceased-donor kidney transplants.
Using the Organ Procurement and Transplant Network-United Network of Organ Sharing database, we identified patients who underwent expanded criteria deceased-donor kidney transplant between January 2000 and December 2008 after receiving induction with rabbit-antithymocyte globulin (n = 3717), alemtuzumab (n = 763), or interleukin 2 blocking agent (n = 2600) followed by calcineurin inhibitor and mycophenolate mofetil-based maintenance with and without steroid therapy.
Adjusted overall graft survival (hazard ratio 1.32; 95% confidence interval, 1.1-1.56; P = .002) and patient survival (hazard ratio 1.46, 95% confidence interval, 1.16-1.83, P = .001) were inferior, whereas death-censored graft survival (hazard ratio 1.13; 95% confidence interval, 0.87-1.47; P = .35) was similar for chronic steroid maintenance versus early steroid withdrawal groups in rabbit-antithymocyte globulin-induced patients. Graft and patient outcomes were similar for chronic steroid maintenance versus early steroid withdrawal groups among alemtuzumab and interleukin 2 blocking agent-induced patients. Among rabbit-antithymocyte globulin-induced patients, adjusted overall graft survival (hazard ratio 1.57; 95% confidence interval, 1.2-2.0; P < .001) and patient survival (hazard ratio 1.5; 95% CI, 1.15-2.1; P = .004) were inferior, whereas death-censored graft survival (hazard ratio 1.5; 95% confidence interval, 0.97-2.43; P = .07) trended inferior for chronic steroid maintenance versus early steroid withdrawal groups in recipients > 60 years old (n = 1729).
Our study showed safety of early steroid withdrawal in recipients of expanded criteria deceased-donor kidney transplants who underwent perioperative induction followed by calcineurin inhibitor and mycophenolate mofetil maintenance. Among rabbit-antithymocyte globulin-induced patients, chronic steroid maintenance was associated with inferior graft and patient outcomes, an effect limited to older recipients.
本研究探讨了扩大标准的已故供体肾移植受者早期停用类固醇的安全性。
利用器官获取与移植网络 - 器官共享联合网络数据库,我们确定了在2000年1月至2008年12月期间接受兔抗胸腺细胞球蛋白诱导(n = 3717)、阿仑单抗(n = 763)或白细胞介素2阻断剂诱导(n = 2600),随后接受钙调神经磷酸酶抑制剂和霉酚酸酯维持治疗且有或无类固醇治疗的扩大标准的已故供体肾移植患者。
在兔抗胸腺细胞球蛋白诱导的患者中,调整后的总体移植物存活率(风险比1.32;95%置信区间,1.1 - 1.56;P = 0.002)和患者存活率(风险比1.46,95%置信区间,1.16 - 1.83,P = 0.001)较低,而慢性类固醇维持组与早期停用类固醇组的死亡审查移植物存活率(风险比1.13;95%置信区间,0.87 - 1.47;P = 0.35)相似。在阿仑单抗和白细胞介素2阻断剂诱导的患者中,慢性类固醇维持组与早期停用类固醇组的移植物和患者结局相似。在兔抗胸腺细胞球蛋白诱导的患者中,60岁以上的受者(n = 1729)中,调整后的总体移植物存活率(风险比1.57;95%置信区间,1.2 - 2.0;P < 0.001)和患者存活率(风险比1.5;95%置信区间,1.15 - 2.1;P = 0.004)较低,而慢性类固醇维持组与早期停用类固醇组的死亡审查移植物存活率(风险比1.5;95%置信区间,0.97 - 2.43;P = 0.07)呈下降趋势。
我们的研究表明,对于接受围手术期诱导、随后接受钙调神经磷酸酶抑制剂和霉酚酸酯维持治疗的扩大标准的已故供体肾移植受者,早期停用类固醇是安全的。在兔抗胸腺细胞球蛋白诱导的患者中,慢性类固醇维持与较差的移植物和患者结局相关,这种影响仅限于老年受者。